Skip to content

MDMA: all studies

Page 31 of 346: studies 301 to 310 of 3,454, newest first. Back to the MDMA overview

Research

Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis

Neuropsychopharmacology April 23, 2024 Julia Colcott, Olivia Carter, Sally Meikle et al. 37 citations

Abstract Evidence suggests that MDMA-assisted psychotherapy (MDMA-AP) has therapeutic potential for treatment of psychiatric illness. We conducted the first comprehensive systematic review and meta-analysis of the side effects of MDMA-AP across indications. We also assessed the quality of side effects-reporting in published trials of MDMA-AP. PubMed, EMBASE, PsycINFO, MEDLINE and Cochrane...

Terapia assistida com 3,4-metilenodioximetanfetamina (MDMA) para o tratamento da ansiedade social em adultos autistas

Research, Society and Development April 11, 2024 Jéssica de Sá Azevedo, Aline da Silva Guerra 1 citation

O transtorno do espectro autista é uma condição no neurodesenvolvimento que causa déficits na interação interpessoal e na comunicação do indivíduo, podendo levar ao desenvolvimento da ansiedade social. A inexistência de um tratamento farmacológico eficaz e com efeitos colaterais reduzidos, tem atraído a atenção dos pesquisadores para o tratamento com abordagens alternativas. O...

Bioisosteric analogs of MDMA with improved pharmacological profile.

bioRxiv : the preprint server for biology April 11, 2024 Ana Sofia Alberto-Silva, Selina Hemmer, Hailey A. Bock et al. preprint

3,4-Methylenedioxymethamphetamine (MDMA, ' ecstasy' ) is re-emerging in clinical settings as a candidate for the treatment of specific psychiatric disorders (e.g. post-traumatic stress disorder) in combination with psychotherapy. MDMA is a psychoactive drug, typically regarded as an empathogen or entactogen, which leads to transporter-mediated monoamine release. Despite its therapeutic...

DOI: 10.1101/2024.04.08.588083 (opens in new tab) Full text (opens in new tab) Psychedelics Drug development Mental health therapy MDMA Research

MDMA (3,4-methylenedioxy-methamphetamine)

Drug Addiction Mechanisms in the Brain April 8, 2024 Jayalakshmi Krishnan 1 citation

3,4-methylenedioxy-methamphetamine (MDMA) is a synthetic drug very similar to hallucinogens and stimulants. This drug is also called ecstasy or molly. It produces feelings of pleasure, warmth, distorted sensory time and perception. MDMA increases the activity of serotonin, dopamine and norepinephrine in the brain. It causes various health effects such as nausea, sweating, chills, muscle...

MDMA-gestützte Therapie

Nervenheilkunde April 1, 2024 Laura Bechtold, Dimitris Repantis

ZUSAMMENFASSUNGNeben den klassischen Psychedelika, z. B. Psilocybin, werden wieder vermehrt andere Substanzen wie 3,4-Methylendioxy-N-methylamphetamin (MDMA) erforscht. Das Entaktogen („innerlich berührend“) ist in den USA nur noch wenige Schritte von einer möglichen Zulassung zur Behandlung der posttraumatischen Belastungsstörung entfernt. Dieser Artikel soll einen Überblick über die Wirkung,...

3,4-Methylenedioxymethamphetamine (MDMA) impairs cognitive function during withdrawal via activation of the arachidonic acid cascade in the hippocampus.

Drug and Alcohol Dependence April 1, 2024 Yoko Nawata, Tsuyoshi Nishioku, Tsuneyuki Yamamoto et al. 2 citations

The recreational drug ±3,4-methylenedioxymethamphetamine (MDMA; also known as "ecstasy") has unusual subjective prosocial and empathogenic effects, and has exhibited potential as an adjunct to psychotherapy in recent years. However, there has been some concern regarding possible neuropsychiatric symptoms, such as cognitive impairment and dependence, emerging after abstinence. Therefore, this...

DOI: 10.1016/j.drugalcdep.2024.111139 (opens in new tab) Full text (opens in new tab) MDMA Cognitive impairment Cyclooxygenase Prostaglandin e2 +4

Harm reduction behaviours and harm experiences of people who use 3,4-methylenedioxymethamphetamine (MDMA) in Aotearoa New Zealand.

Harm Reduction Journal March 21, 2024 Jai Whelan, Geoff Noller, Ryan D Ward 6 citations

3,4-Methylenedioxymethamphetamine (MDMA) is drug of high prevalence in Aotearoa New Zealand and is the primary drug analysed by legal drug checking services. We aimed to address the gap in literature pertaining to MDMA-related harm reduction behaviour and harm experiences within the country. An online survey was used to assess the harm reduction behaviours (e.g., limiting consumption, planning...

MDMA enhances positive affective responses to social feedback.

Journal of Psychopharmacology March 1, 2024 Anya K. Bershad, David T Hsu, Harriet de Wit 9 citations

The prosocial compound ± 3,4-methylenedioxymethamphetamine (MDMA) is an amphetamine derivative that has shown promise as an adjunct to psychotherapy in the treatment of post-traumatic stress disorder. MDMA increases positive responses to social images, and it has been suggested that the ability of MDMA to positively bias social perception may underlie its therapeutic efficacy as a psychotherapy...

DOI: 10.1177/02698811231224153 (opens in new tab) Full text (opens in new tab) MDMA Social acceptance Social feedback Social rejection

Recreational MDMA doses do not elicit hepatotoxicity in HepG2 spheroids under normo- and hyperthermia.

Toxicology March 1, 2024 Arthur L. De Oliveira, Raul G Miranda, Daniel J Dorta 1 citation

MDMA (3,4-methylenedioxymethamphetamine), an entactogen with empathogenic and prosocial effects, is widely used in music festivals and other festive settings. High MDMA doses have been associated with drug-induced liver injury and cases of hyperthermia. Although the latter condition is thought to increase MDMA hepatotoxicity, this correlation remains poorly explored for recreational MDMA doses....

DOI: 10.1016/j.tox.2024.153761 (opens in new tab) Full text (opens in new tab) Tridimensional cell culture Drug research MDMA/Ecstasy/Molly/E Liver toxicity/hepatotoxicity/citotoxicity